Navigation Links
Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology

Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans and that results from one study may necessarily not be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2006, our 10-Q for the three months ending March 31,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
Post Your Comments:
(Date:9/1/2015)... On August 31, 2015, United States District ... 123-page order in the first of the consolidated MDL ... replacement devices are defective.[1]  The Court ... Robyn Christiansen,s claims for defective design, fraudulent misrepresentation and ... Medical,s claim that the Medical Device Amendment to the ...
(Date:9/1/2015)... , Sept. 1, 2015  Amgen (NASDAQ: ... Novartis in the areas of Alzheimer,s disease and ... Alzheimer,s disease by teaming up with Novartis on ... directed at genetically predisposed individuals at risk of ... focus on the commercialization of its migraine programs ...
(Date:9/1/2015)... and Delaware , United ... (ASX: IVX; "Company" or "Invion"), is pleased to announce that ... securities to an institutional investor in the United ... proceeds of approximately A$1.001 million ("Placement") by the issue of ... of $0.014 per share. The Company has ...
Breaking Medicine Technology:Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 2Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3
... Reportlinker.com announces that a new market research report is available in its catalogue: , ... Relieving Drug Market Analysis 2010-2025 , , , ... , Reports details , ... opportunities lie in this diverse market with high, growing demand worldwide? , , ...
... WESTLAKE VILLAGE, Calif. , May 4 ... provider of specialty physician consultations via telemedicine, announced today ... Organization,s 2010 Innovations in Healthcare ABBY Award.  SOC won ... category for their 24/7 teleneurology service that provides immediate ...
Cached Medicine Technology:Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 2Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 3Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 4Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 5Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 6Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 7Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 8Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 9Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 10Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 11Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 12Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 13Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 14Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 15Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 16Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 17Specialists On Call Wins 2010 Innovations in Healthcare ABBY Award 2
(Date:9/1/2015)... ... September 01, 2015 , ... The ... the treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, Capillus, ... while also demonstrating its safety when used at home to combat hair loss. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab Physical Therapy , ... partnership with Apex Physical Therapy (Apex) is official as of August ... compassionate, and empathetic care to local residents from their combined eight locations throughout ...
(Date:9/1/2015)... ... , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of ... has taken place at Kingsborough Community College in Brooklyn in each of the past ... Calvary, and two junior counselors who were campers themselves just a few years ago. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... cure and prevent different malignancies. Some options for cancer treatment are available ... to which distinctive approach is necessary for effective treatment. Several molecules have ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... creates negative pressure inside a wound to remove exudates, fluid, and infectious materials ... (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected to ...
Breaking Medicine News(10 mins):Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
... Tools to Help Make More ,Cents, of,Grocery Bills, WASHINGTON, ... celebrity to join the famed Milk Mustache campaign, this time,to ... many,families are economizing on groceries but one thing they should ... 8 ounce glass, on a gallon,basis, milk offers more nutrients ...
... On September 30, 2008,viewers tuning in to ... ) will find hope for stuttering. That day, ... M.A., CCC-SP,founder of Power Stuttering Center ( http://www.powerstuttering.com ... eliminated by the SpeechEasy(R),Stuttering Device., Power, a ...
... Open enrollment season,throughout corporate America is rapidly approaching, ... important decisions about their employee,benefit coverage for next ... an,increased emphasis on personal health behaviors as well ... services and programs, according to,benefit consultants at Watson ...
... offers no concrete answers , , MONDAY, Sept. 29 (HealthDay News) ... more likely to die after surgery than those who live ... study analyzed death rates among more than one million older ... cancer surgeries between 1999 and 2003. , The risk ...
... ... Study, ... released its first study: "Choosing a Health Plan:,What Should Consumers Look ... statements designed,to help create more informed consumers and improve health care ...
... Industries,Inc. (Nasdaq: HRLY ) announced today that ... a contract totaling approximately $1.3 million,from Lockheed Martin ... switch filter assemblies for the MH-60R helicopter in ... Multi-Mission Helicopter (MMH) is the U.S. Navy,s new,primary ...
Cached Medicine News:Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 2Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 3Health News:Help for Stutterers on 'The Doctors' TV Show Presented by Power Stuttering Center Founder Mark Power 2Health News:Watson Wyatt Identifies Trends for Benefits Open Enrollment Season 2Health News:Watson Wyatt Identifies Trends for Benefits Open Enrollment Season 3Health News:Seniors in Poor Areas More Likely to Die After Surgery 2Health News:Access to Physicians Is Consumers' Highest Priority When Choosing a Health Plan, According to New Study 2Health News:Access to Physicians Is Consumers' Highest Priority When Choosing a Health Plan, According to New Study 3Health News:Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: